Skip to content
Open access

Real-world efficacy and safety of neoadjuvant immunochemotherapy in patients with triple-negative breast cancer.

Oct 2026 · Immunotherapy · pp. 1-12 · 0 citations · 27 references
Medicine

TL;DR

Compared with NAC alone, NAIC significantly improves the pCR rate and reduces the recurrence risk in TNBC patients, with generally manageable toxicity in this real-world cohort, which supports its favorable clinical application value.

Abstract

Aim

To evaluate the real‑world efficacy and safety of adding programmed cell death protein 1 (PD-1) inhibitors to neoadjuvant chemotherapy in Chinese patients with triple‑negative breast cancer (TNBC). PATIENTS AND

Methods

This single-center retrospective study enrolled 218 TNBC patients receiving neoadjuvant therapy, including 116 in the neoadjuvant chemotherapy (NAC) cohort and 102 in the neoadjuvant immunochemotherapy (NAIC) cohort. Clinical, biological, pathological and therapeutic data were collected. Primary endpoints were pathological complete response (pCR) and event-free survival (EFS).

Results

Multivariate analysis showed Ki-67 >30% (p = 0.003) and PD-1 inhibitor addition (p < 0.001) were independently associated with higher pCR. NAIC significantly reduced recurrence (7.8% vs. 25.0%, p < 0.001). Miller-Payne grades 2-4 were independent prognostic factors for improved EFS compared with grade 1 (all p < 0.05); grade 5 was excluded due to collinearity with pCR. Except for immune-related adverse events (irAEs), the incidence of other adverse events (AEs) showed no significant differences between the two groups (all p > 0.05).

Conclusions

Compared with NAC alone, NAIC significantly improves the pCR rate and reduces the recurrence risk in TNBC patients, with generally manageable toxicity in this real-world cohort, which supports its favorable clinical application value.

Read PDF

Similar papers

Review Open access Oct 2026

Real-world pathologic complete response after neoadjuvant chemotherapy in a safety-net breast cancer population.

556 Background: While clinical trials report subtype-specific pathologic complete response (pCR) rates, real-world data from safety-net health systems remain limited and underrepresented in major neoadjuvant trials. Our urban safety-net patient population in Oakland, CA, provides a unique view of real-world neo...

Nancy T. Nguyen, Chun-Yin Chow, Nguyen Nguyen et al. · 0 citations
Open access Oct 2026

The Impact of adding platinum-base Regime for Neoadjuvant therapy in Patient with Triple- Negative Breast Cancer patients. A Retrospective Study

Objective: To evaluate the impact of incorporating platinum-based agents into neoadjuvant chemotherapy regimens on achieving pathological complete response in patients with triple-negative breast cancer. Method: The retrospective, cohort study was conducted in March 2025 at the Dow University Hospital, Karachi, and com...

Rutaba Alam, Omema Saleem, Maryum Nouman et al. · 0 citations
Open access Sep 2026

Greater survival benefits in small cell lung cancer patients: a real-world study with immune checkpoint inhibitors therapy

Real-world evidence is provided supporting the use of ICI-based therapy in SCLC, particularly in advanced-stage disease, but should be interpreted cautiously given the retrospective design and subgroup sample sizes.

Peng-Hu Gao, Hong-Bing Zhang, Ming-Hui Liu et al. · 0 citations
Open access Nov 2026

Neoadjuvant immunochemotherapy vs. neoadjuvant chemotherapy or concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma.

NICT was associated with improved survival compared with either NCT or CCRT, and these findings are hypothesis-generating and require prospective validation.

Run-Zhi Wang, Cheng-Xian Ma, Huan-Wei Liang et al. · 0 citations
Open access Oct 2026

Correlation Between Interleukin-33 Expression and Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Introduction: Locally advanced breast cancer (LABC) is associated with high morbidity. While neoadjuvant chemotherapy (NAC) is the standard of care, clinical responses vary significantly due to tumor heterogeneity. This study evaluated pre-treatment intracellular Interleukin-33 (IL-33) expression as an independent pred...

Rachmad Meyliandry Putra, Nilam Smaradhania, Indra Indra et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.